Firategrast, an oral formulation of a natalizumab-like small molecule, produces a significant reduction in MRI lesions, according to the results of a phase II study (Miller et al. Lancet Neurol 2012; epublished January 5, 2012).
It takes 30 seconds or login using your email address
Please enter the email address that you registered the newsletter with
